|
Patent landscape, scope, and claims summary: |
United States Patent 10,000,547: Claim Integrity, Likely Claim Scope, and How the Landscape Shapes Validity and Freedom-to-Operate
US Patent 10,000,547 centers on a cancer immunotherapy method that administers a composition containing activated T lymphocytes that selectively recognize patient cells aberrantly expressing a specific peptide sequence, “YLMDDFSSL” (SEQ ID NO: 21). The activated T cells are presented as cytotoxic T cells generated by contacting T cells with an antigen presenting cell (APC) presenting the peptide in complex with MHC class I. The claims then broaden in method steps (autologous or allogeneic sources, ex vivo expansion, use of adjuvants, recombinant virus APCs, dendritic cells or macrophages, CD28 plus IL-12 stimulation) and expand applicability across a wide cancer panel that includes both solid tumors and hematologic malignancies.
What exactly does Claim 1 require?
Claim 1 is a method claim with a defined antigen and defined immunologic activation context. A single accused method must satisfy each of these core limitations, in combination:
Core limitation set (Claim 1)
- Patient with cancer
- Cancer is selected from a long list including HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, breast cancer, CLL, MCC, SCLC, NHL, AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), UBC, and uterine cancer (UEC).
- Administration of a composition containing a population of activated T lymphocytes
- The T lymphocytes “selectively recognize cells in the patient” that aberrantly express a peptide.
- The peptide is fixed by sequence
- Peptide consists of amino acid sequence YLMDDFSSL (SEQ ID NO: 21).
- Mechanism of cytotoxic T cell activation is fixed
- The activated T cells are cytotoxic T cells produced by contacting T cells with an APC that:
- expresses the peptide, and
- presents it in complex with MHC class I on the APC surface.
- Time sufficient to activate
- Contacting is “for a period of time sufficient” to activate T cells specifically against the peptide.
Claim 1 scope implications
- The antigen is the anchor. If an accused therapy targets a different peptide or a different epitope (even a closely related one), it does not literally meet the “peptide consists of” requirement.
- The activation pathway is the second anchor. Claim 1 requires that the cytotoxic T cells are produced by ex vivo (or at least defined) contacting with APCs presenting peptide in MHC class I. A method that administers pre-existing cytotoxic T cells generated by different priming systems (for example, direct peptide-loaded HLA complexes without APC involvement, or CAR-T, or TCR-engineered approaches) may avoid literal coverage depending on how “contacting with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule” is interpreted.
Dependent claims: the patent’s “control points” for narrowing or design-around
Claims 2 through 13 add alternative sources, manufacturing steps, adjuvant compositions, viral APC expression, and stimulation conditions. These dependent claims likely function as both (a) fallback positions for infringement arguments and (b) design-around levers.
What do claims 2–4 do to the method’s accused classes?
| Dependent claim |
Additional limitation |
Practical consequence for infringement analysis |
| Claim 2 |
T cells are autologous |
Narrows to patient-derived T cells. Allogeneic-only approaches avoid this specific dependent claim while leaving Claim 1 still potentially in play. |
| Claim 3 |
T cells are obtained from a healthy donor |
Narrows to donor-derived T cells, potentially broadening practical use but still tethered to Claim 1’s peptide and APC/MHC class I presentation. |
| Claim 4 |
T cells obtained from tumor infiltrating lymphocytes or PBMC |
Adds sourcing options that are common in T cell immunotherapy workflows. Avoidance here would require using other starting materials. |
How do claims 5–6 address manufacturing steps and presentation form?
| Dependent claim |
Additional limitation |
Scope/validity leverage |
| Claim 5 |
Further comprising expanding T cells in vitro |
This is standard in adoptive T cell protocols. It will be hard to design around if the accused method includes expansion. |
| Claim 6 |
Peptide is in a complex with an MHC molecule |
Likely clarifies that peptide presentation is via an MHC complex. However Claim 1 already requires peptide presented in MHC class I on APC surface. Claim 6 reads like a redundancy that may matter for interpretation of the “peptide expressed” versus “peptide presented” elements. |
Which adjuvant and co-stimulation options does claim 8 and claim 11 create as coverage expansions?
Claim 7 and Claim 8 allow adjuvants. Claim 11 adds a specific co-stimulation regime.
Adjuvant list in Claim 8 (wide but checkable)
Claim 8 enumerates adjuvants including:
- Imiquimod
- Resiquimod
- GM-CSF
- Cyclophosphamide
- Sunitinib
- Bevacizumab
- Interferon-alpha
- CpG
- “Oligonucleotides and derivatives”
- Poly-(I:C) and derivatives
- RNA
- Sildenafil
- “Particulate formations with PLG and virosomes”
Impact: This list is broad, and many are commonly used immune modulators, cytokines, checkpoint-context modifiers, or delivery vehicle components. A method that uses any of these as part of the administered composition could match Claim 7/8 if other elements are satisfied.
Design-around leverage: If a competitor uses a different adjuvant not on the list, it may avoid the dependent claims but still potentially infringe Claim 1 if the adjuvant is not a required limitation. Since Claim 1 does not require an adjuvant, avoiding Claim 8 does not eliminate exposure to Claim 1.
Co-stimulation and clonal expansion in Claim 11
Claim 11 adds:
- stimulating activated T cells in the presence of:
- anti-CD28 antibody, and
- IL-12
- to clonally expand T cells
Impact: This is a specific manufacturing condition. A competitor that uses different cytokines or co-stimulation (for example, IL-2 with anti-CD3, IL-7/IL-15, or other systems) may avoid Claim 11 while still leaving Claim 1 infringement risk intact.
How does claims 9–10 expand the activation mechanism beyond typical APC loading?
Viral expression pathway
- Claim 9: APC is infected with a recombinant virus expressing the peptide.
- Claim 10: APC is a dendritic cell or macrophage.
Interpretation leverage: These dependent claims likely target methods where peptide presentation occurs via endogenous expression after viral infection rather than exogenous peptide loading. If an accused method uses direct peptide loading onto APCs (without recombinant viral infection), it may avoid claims 9–10.
Design-around leverage: A competitor using DC maturation and peptide loading without recombinant viral infection may avoid these dependent claims.
How does Claim 12 and 13 refine the T cell phenotype and contacting context?
- Claim 12: composition comprises CD8-positive cells.
If a method uses mixed T cell subsets (including CD4) as the effector or does not enrich CD8, it may reduce likelihood of satisfying this dependent claim. Claim 1 still requires cytotoxic T cells; in many contexts cytotoxic function maps to CD8, but claim language can become interpretive.
- Claim 13: contacting is in vitro.
This narrows to ex vivo priming. If a therapy primes in vivo using APCs in the patient, it might avoid this dependent claim while still potentially implicating Claim 1 depending on how the overall method is structured.
Patent landscape and claim-criticality: what matters for validity and market risk
Because the claim set is heavily anchored on one peptide sequence and one antigen presentation context (MHC class I on APC surface), the landscape turns primarily on:
- Whether YLMDDFSSL (SEQ ID NO: 21) is previously disclosed as a cancer epitope
- Whether prior art already taught activating cytotoxic T lymphocytes with that epitope using APC-mediated MHC I presentation
- Whether a prior method disclosed the same therapeutic “method of eliciting immune response in cancer patients” using patient-specific aberrant peptide recognition
- Whether manufacturing elements (expansion, CD28+IL-12) are already widely used with the same peptide-specific approach
- Whether any prior art references disclose the broad cancer applicability list, or whether the claims overreach by covering unrelated tumors without a demonstrated mechanistic link
Key validity pressure points
The patent’s strongest vulnerability typically arises from:
- Single fixed peptide sequence: if that epitope was known from immunology literature or earlier patents as a tumor-associated epitope, then the novelty of the peptide-based claim may be undermined. The phrase “selectively recognize cells ... aberrantly express a peptide” reads like a typical tumor antigen presentation narrative; if that story was already in the prior art for the same epitope, the method claim may be obvious.
- APC + MHC I + cytotoxic T cells: these three elements are the core of classic MHC class I antigen presentation and CD8 cytotoxic priming. If prior art already used this architecture with YLMDDFSSL, the incremental novelty collapses into implementation choices.
- Broad cancer panel: a wide list of indications increases risk under enablement and written description arguments if the specification did not support each cancer type with data tied to that epitope. Even when the peptide is relevant to multiple tumor types via shared antigen expression, prior art and disclosure strength matter.
Key infringement exposure drivers (practical)
For a potential infringement scenario, a challenger or market entrant should map their protocol against the claim’s hard points:
- Is the exact peptide sequence YLMDDFSSL used?
- Are the administered cells activated cytotoxic T cells generated by contacting T cells with APCs presenting that peptide in MHC class I?
- Is the administration “to a patient who has cancer” and does the method select cancers within the listed set?
- Does the method include any dependent steps (adjuvant; recombinant viral infection of APCs; CD28+IL-12 stimulation; CD8 enrichment; in vitro contacting)?
A competitor can often design around dependent claims, but Claim 1 is broad enough that the peptide and APC/MHC I cytotoxic priming pathway are the true gating items.
What claims create the cleanest design-around paths?
The dependent claims offer possible narrow detours, but the most reliable design-around attempts usually avoid one of Claim 1’s anchors. Based on the claim text, the cleanest routes are:
- Different peptide or variant epitope strategy
- Claim 1 requires the peptide “consists of” YLMDDFSSL. Using a different peptide sequence is the most direct literal-avoidance route.
- Different antigen presentation activation architecture
- If T cells are activated without APC expressing the peptide in MHC class I on the APC surface, a method may miss Claim 1’s activation mechanism.
- Non-MHC I priming (if truly outside the claim)
- Strategies that focus on MHC II or alternative immune activation pathways likely avoid the MHC class I on APC surface requirement.
- In vivo priming without in vitro contacting
- This primarily addresses Claim 13, not Claim 1, but it can reduce the claim’s manufacturing specificity in any infringement narrative.
Key Takeaways
- US 10,000,547 Claim 1 is anchored to a single epitope sequence (YLMDDFSSL) and a defined APC-MHC class I cytotoxic T cell activation pathway, then broadly applies to a wide panel of cancers.
- Dependent claims add practical manufacturing and formulation options (autologous/allogeneic source, expansion, adjuvants, recombinant viral infected APCs, DC/macrophage identity, anti-CD28 + IL-12 clonal expansion, CD8 enrichment, in vitro contacting). These can be easier to route around than Claim 1’s anchors, but avoiding dependents does not avoid Claim 1.
- The landscape’s validity pressure points are the likely availability of prior art for (a) the epitope itself and (b) APC-mediated MHC I cytotoxic priming methods using that epitope.
- The main infringement risk hinge for market entrants is whether their therapy uses the exact peptide sequence and the APC-MHC I cytotoxic priming mechanism required by Claim 1.
FAQs
-
Is the adjuvant required to infringe?
No. Claim 1 does not require an adjuvant. Claims 7–8 add adjuvant limitations only to dependent coverage.
-
Can a method avoid dependent claims while still infringing Claim 1?
Yes. If a protocol uses the peptide and the APC/MHC class I cytotoxic activation framework but differs in adjuvant choice, viral infection, or CD28+IL-12 stimulation, it may still meet Claim 1.
-
Does the patent cover only CD8 T cells?
Claim 1 requires cytotoxic T cells. Claim 12 explicitly adds CD8-positive cells only as a dependent limitation.
-
How strong is the claim’s specificity?
It is highly specific on the peptide sequence (YLMDDFSSL) and on APC-mediated MHC class I presentation used to generate activated cytotoxic T cells.
-
Which design-around strategy is most direct?
Using a different antigen peptide sequence (not “consists of YLMDDFSSL”) or activating T cells through a pathway that does not involve APCs presenting that peptide in complex with MHC class I.
References
[1] US Patent 10,000,547 (claims as provided in prompt).
More… ↓
⤷ Start Trial
|
